Malignant melanoma remains one of the fastest growing cancers worldwide. In 2014 an estimated 112,200 patients will be diagnosed with malignant melanoma in the United States and five major European markets. Although the primary cutaneous melanoma can be managed by surgery, the advanced metastatic melanoma cannot be managed by surgery alone and thus, requires better therapeutic approaches. Diagnosis of melanoma can be accomplished through clinician assessment of the skin lesion with the unaided eye. Research in melanoma diagnostics has also focused on detecting melanoma-specific biological markers such as is Microphthalmia transcription factor (Mitf) that helps predict the course of the disease and also the probability that the patient will experience remission of metastatic melanoma. The metastatic or unresectable disease can be treated with immunotherapy, or with targeted therapy. For immunotherapy, PD-1 inhibitor monotherapy with pembrolizumab or nivolumab, or the combination of nivolumab and ipilimumab is recommended, whereas for targeted therapy, combination therapy with dabrafenib/trametinib or vemurafenib/cobimetinib is recommended. Standard therapy with for unresectable malignant melanoma with cytotoxic therapy agents such as dacarbazine, temozolomide and IL-2 is associated with notoriously lower response rates. In recent years, better understanding of melanoma biology, as well as cancer and immune biology in general has led to the development of a number of new potential therapeutic agents for advanced melanoma. These advancements in molecularly targeted inhibitors such as Vemurafenib (Zelboraf, BRAF V600 inhibitor) and Ipilimumab (Yervoy, monoclonal antibody against the CTLA-4 protein) have shown improved average overall survival outcomes for metastatic melanoma patients compared to vaccine therapy. In 2013, two additional targeted therapies, dabrafenib (Tafinlar) and trametinib (Mekinist), as well as the ThxID-BRAF companion diagnostic test were approved, whereas several BRAF and MEK inhibitors such as cobimetinib, binimetinib, and programmed cell death protein 1 (PD1)-directed monoclonal antibodies, a novel class of immune checkpoint inhibitors, such as pembrolizumab and nivolumab are in clinical development.
The global malignant melanoma therapeutics market segmentation is based on drug class (cytotoxic agents, cytokines and viral vector vaccines, BRAF and MEK inhibitors, immune checkpoint inhibitors).
The global malignant melanoma therapeutics market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global malignant melanoma therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global malignant melanoma therapeutics market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global malignant melanoma therapeutics market and profiled in this report include Amgen, Array BioPharma, BioMérieux, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo, Exelixis, GlaxoSmithKline, Merck & Co., Navidea Biopharmaceuticals, Inc., Novartis, Ono Pharmaceutical Co. Ltd., and Roche (Genentech).